Charles Schwab
KLDO

Charles Schwab’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Charles Schwab’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-41,084
Closed -$68K – 3730
2022
Q1 		$68K Sell
41,084
-8,510
-17% -$15.2K ﹤0.01% 3484
2021
Q4 		$119K Hold
49,594
– – ﹤0.01% 3421
2021
Q3 		$271K Sell
49,594
-90,884
-65% -$564K ﹤0.01% 3287
2021
Q2 		$1.05M Buy
140,478
+14,566
+12% +$103K ﹤0.01% 2910
2021
Q1 		$1.02M Buy
125,912
+35,348
+39% +$385K ﹤0.01% 2853
2020
Q4 		$825K Sell
90,564
-4,850
-5% -$39.8K ﹤0.01% 2828
2020
Q3 		$1.06M Buy
95,414
+55,094
+137% +$382K ﹤0.01% 2664
2020
Q2 		$300K Sell
40,320
-897
-2% -$6.01K ﹤0.01% 3048
2020
Q1 		$254K Buy
41,217
+402
+1% +$2.62K ﹤0.01% 2944
2019
Q4 		$205K Buy
40,815
+12,796
+46% +$81.3K ﹤0.01% 3036
2019
Q3 		$211K Sell
28,019
-2,370
-8% -$20.6K ﹤0.01% 3033
2019
Q2 		$353K Buy
+30,389
New +$443K ﹤0.01% 2964

Other funds holding KLDO

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Charles Schwab's KLDO Position: Q2 2022 in Review

Charles Schwab sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2022, closing a stake of 41,084 shares — an estimated $68K sold.

Charles Schwab first reported a position in KLDO in Q2 2019 and held it in 12 quarters. The position peaked at $1.06M in Q3 2020. 3 funds tracked by Wall St. Rank hold KLDO as of Q2 2022.

  • Charles Schwab reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Charles Schwab sold 41,084 Kaleido Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $68K.
  • Charles Schwab first reported a position in Kaleido Biosciences, Inc. Common Stock in Q2 2019 and held it in 12 quarters.
  • Charles Schwab's Kaleido Biosciences, Inc. Common Stock position peaked at $1.06M in Q3 2020.
  • 3 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2022.

Based on Charles Schwab's 13F filing for Q2 2022, filed 15 Aug 2022.